Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (281-290 of 443) with videos related to

Pageof 45
Sort By:
Blood Advances|January 4, 2018
Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseasesJohn A Snowden, Manuela Badoglio, Myriam Labopin, et al.
Cancer Medicine|November 26, 2020
Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Edouard Forcade, et al.
Cancer|September 16, 2022
Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMTArnon Nagler, Myriam Labopin, Mutlu Arat, et al.
Bone Marrow Transplantation|November 22, 2025
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMTKordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, et al.
Bone Marrow Transplantation|March 30, 2024
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Nicolaus Kröger, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|September 16, 2022
Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMTArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
American Journal of Hematology|April 1, 2018
Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatoryJean-Antoine Ribeil, Myriam Labopin, Aurélie Stanislas, et al.
Haematologica|September 26, 2015
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease statusAli Bazarbachi, Myriam Labopin, Mohamed A Kharfan-Dabaja, et al.
Cancer|September 2, 2023
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Urpu Salmenniemi, et al.
Pageof 45

Showing results (281-290 of 443) with videos related to

Sort By:
Pageof 45
Blood Advances|January 4, 2018
Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseasesJohn A Snowden, Manuela Badoglio, Myriam Labopin, et al.
Cancer Medicine|November 26, 2020
Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Edouard Forcade, et al.
Cancer|September 16, 2022
Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMTArnon Nagler, Myriam Labopin, Mutlu Arat, et al.
Bone Marrow Transplantation|November 22, 2025
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMTKordelia Barbullushi, Myriam Labopin, Nicolaus Kröger, et al.
Bone Marrow Transplantation|March 30, 2024
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Myriam Labopin, Nicolaus Kröger, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Bone Marrow Transplantation|September 16, 2022
Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMTArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
American Journal of Hematology|April 1, 2018
Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatoryJean-Antoine Ribeil, Myriam Labopin, Aurélie Stanislas, et al.
Haematologica|September 26, 2015
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease statusAli Bazarbachi, Myriam Labopin, Mohamed A Kharfan-Dabaja, et al.
Cancer|September 2, 2023
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Urpu Salmenniemi, et al.
Pageof 45